Advantages of SC HER2 Therapy Over IV Administration in Breast Cancer
March 7th 2024Rebecca A. Shatsky, MD, discusses the advantages of giving patients with HER2-positive breast cancer a subcutaneous injection of targeted therapy compared with the intravenous formulation of trastuzumab and pertuzumab.
Watch
Promising New Therapy for Hematologic Malignancies in Young Patients
February 28th 2024Alice Bertaina, MD, discusses combining of T-allo10, a donor-derived cell product, with haploidentical stem cell transplants for the treatment of pediatric and young adult patients with hematologic malignancies.
Watch